A comparative study of escitalopram ,placebo and relaxation on hot flashes of patients with breast cancer

Vice chancellor for Research, Kermanshah University of Medical Sciences0 sites87 target enrollmentTBD

Overview

Phase: Phase 3
Intervention: Not specified
Conditions: Not specified
Sponsor: Vice chancellor for Research, Kermanshah University of Medical Sciences
Enrollment: 87
Status: Recruiting
Last Updated: 8 years ago

Overview Investigators Eligibility Criteria Outcomes Similar Trials

Overview

Brief Summary

No summary available.

Registry

who.int

Start Date

TBD

End Date

TBD

Last Updated

8 years ago

Study Type

Interventional

Sex

Female

Investigators

Sponsor

Vice chancellor for Research, Kermanshah University of Medical Sciences

Eligibility Criteria

Inclusion Criteria

•having at least 4 hot flash attacks daily; Age range is 18 to 65 years; a history of breast cancer; not in acute phase of breast cancer, Ability to read and write and being able to answer questions ;Consent to participate in the study; Not concurrent using of any drugs that affect hot flash symptoms such as gabapentin, pregabalin, clonidine, SSRIs, herbal drugs and other treatments such as acupuncture, hypnotism ; no Non\-malignant hypertension or CVA or MI or other uncontrolled organic problems and psychotic or bipolar disorders
•Exclusion criteria: incidence of intolerable drug side effects, breast cancer relapse needing chemotherapy

Exclusion Criteria

Not provided

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed

Phase 2

Evaluation of the effect of Escitalopram versus placebo trial on changing the neuroticismeuroticism or neuroticism.Post-traumatic stress disorder, acuteF43.11

IRCT20211208053331N1Ahvaz University of Medical Sciences172

Recruiting

Phase 3

Treatment of depressive symptoms in patients with heart failureDepression.Major depressive disorder, single episode, mildF32.0

IRCT20190525043700N5Babol University of Medical Sciences80

Terminated

Phase 4

Wellness StudyChronic illness - patients who are generally unwell for an extended period.Other - Conditions of unknown or disputed aetiology (such as chronic fatigue syndrome/myalgic encephalomyelitis)

ACTRN12608000398303Mood Research Foundation (WA)50

Completed

Not Applicable

Efficacy and tolerability of escitalopram versus paroxetine-CR in Japanese patients with major depressive disorder: a randomized, masked-rater trialmajor depressive disorder

JPRN-UMIN000011191Department of Psychiatry, Fujita Health University School of Medicine200

Active, not recruiting

Phase 1

A Randomised Controlled Trial of Escitalopram and Nortriptyline compared with placebo, and standard psychological care, for depression in Parkinson’s diseaseDepression in Parkinson's diseaseMedDRA version: 20.0Level: PTClassification code 10012378Term: DepressionSystem Organ Class: 10037175 - Psychiatric disordersMedDRA version: 20.0Level: PTClassification code 10061536Term: Parkinson's diseaseSystem Organ Class: 10029205 - Nervous system disordersTherapeutic area: Diseases [C] - Nervous System Diseases [C10]

EUCTR2018-002942-35-GBniversity College London Comprehensive Clinical Trials Unit408